Search results

Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Last updated

20 May 2024

This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

Result type

NICE guideline

Published

23 January 2018

Discontinued [GID-TAG280]

Result type

Technology appraisal guidance

Status

Discontinued

Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema in adults.

Result type

Technology appraisal guidance

Last updated

26 October 2023

Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.

Result type

Technology appraisal guidance

Published

24 July 2013

2003 TA155 Macular degeneration (age-related) - ranibizumab and pegaptanib 30 June 2008 TA237 Macular oedema (diabetic) - ranibizumab:...

Evidence-based recommendations on limited macular translocation for wet age related macular degeneration. This involves cutting and moving the macula on an a nearby healthier area of the retina.

Result type

Interventional procedures guidance

Published

19 May 2010

Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.

Result type

Technology appraisal guidance

Last updated

20 May 2024

NICE has developed a medtech innovation briefing (MIB) on Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema .

Result type

Medtech innovation briefing

Published

24 April 2018